CD19 Protein (C-His, Human)

1.Flow cytometric analysis of anti-CD19 CAR expression. 5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:125 dilution (0.8 μL stock solution in 100 μL FACS buffer) of APC-conjugated human CD19 Protein (Site-Specific APC-Conjugated, ECD, His Tag, Cat. No. 11880-H08W1-SA) and negative control protein. Non-transduced 293 cells were used as a control (left) . APC signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of APC-conjugated CD19 protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and APC-conjugated human CD19 Protein (Site-Specific APC-Conjugated, ECD, His Tag, Cat. No. 11880-H08W1-SA) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) . 3.Flow cytometric analysis using APC conjugated CD19 protein. 5e5 of anti-CD19 CAR-293 cells were stained with APC-conjugated human CD19 protein (Site-Specific APC Conjugation, ECD, His Tag, Cat. No. 11880-H08W1-SA) . Non-transduced 293 cells were used as a control (Black Histogram) . The protein exhibited stable performance after multiple freeze-thaw cycles (10 cycles) 4.Flow cytometric analysis using APC conjugated CD19 protein. 5e5 of anti-CD19 CAR-293 cells were stained with APC-conjugated human CD19 protein from two vendors (competitor A and SINO) . Non-transduced 293 cells were used as a control (Black Histogram) . The results demonstrated that SINO’s 11880-H08W1-SA has a higher fluorescence intensity than that of the competitor.